Uniqure NV (NASDAQ:QURE) CEO Matthew C. Kapusta sold 8,000 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $71.45, for a total value of $571,600.00. Following the completion of the sale, the chief executive officer now owns 404,839 shares in the company, valued at approximately $28,925,746.55. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of NASDAQ QURE opened at $72.37 on Monday. Uniqure NV has a 1-year low of $21.98 and a 1-year high of $82.49. The stock has a market cap of $2.74 billion, a P/E ratio of -30.93 and a beta of 1.05. The company has a current ratio of 9.51, a quick ratio of 9.51 and a debt-to-equity ratio of 0.38. The business’s 50-day moving average is $73.20.
Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. The business had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $2.00 million. Analysts anticipate that Uniqure NV will post -3 EPS for the current year.
QURE has been the topic of several recent research reports. Zacks Investment Research downgraded Farmland Partners from a “hold” rating to a “sell” rating in a report on Friday, July 12th. Robert W. Baird initiated coverage on Uniqure in a report on Thursday, March 28th. They set an “outperform” rating and a $85.00 price target on the stock. BidaskClub upgraded Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. SunTrust Banks upped their price target on Everbridge to $87.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Finally, HC Wainwright set a $73.00 price target on Uniqure and gave the stock a “buy” rating in a report on Monday, July 8th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Uniqure presently has an average rating of “Buy” and an average target price of $78.18.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harvest Group Wealth Management LLC purchased a new position in shares of Uniqure in the 1st quarter valued at about $26,000. Advisor Group Inc. boosted its position in shares of Uniqure by 5.3% in the 4th quarter. Advisor Group Inc. now owns 9,966 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 502 shares during the period. Pearl River Capital LLC acquired a new stake in shares of Uniqure in the 1st quarter valued at about $32,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Uniqure by 14.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,045 shares of the biotechnology company’s stock valued at $301,000 after purchasing an additional 648 shares during the period. Finally, Legal & General Group Plc boosted its position in shares of Uniqure by 264.2% in the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 700 shares during the period. Institutional investors and hedge funds own 60.10% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: What are Closed-End Mutual Funds?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.